ADVMdelisted
Adverum Biotechnologies, Inc.
Biological products·Phase 3·CEO: Stockholders
Laurent Fischer, M.D.
Gene TherapyOphthalmology
Run Adverum Biotechnologies, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adverum Biotechnologies, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Governance
Frequently asked questions
Who is the CEO of Adverum Biotechnologies, Inc.?
Stockholders Laurent Fischer, M.D. is the chief executive officer of Adverum Biotechnologies, Inc. (ADVM).
What therapeutic areas does Adverum Biotechnologies, Inc. focus on?
Adverum Biotechnologies, Inc. develops therapies across Gene Therapy, Ophthalmology.
923 companies304,841 SEC filings22,642 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.